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ABSTRACT
Objectives To compare the efﬁcacy and safety of SB4
(an etanercept biosimilar) with reference product etanercept
(ETN) in patients with moderate to severe rheumatoid
arthritis (RA) despite methotrexate (MTX) therapy.
Methods This is a phase III, randomised, double-blind,
parallel-group, multicentre study with a 24-week primary
endpoint. Patients with moderate to severe RA despite MTX
treatment were randomised to receive weekly dose of
50 mg of subcutaneous SB4 or ETN. The primary endpoint
was the American College of Rheumatology 20% (ACR20)
response at week 24. Other efﬁcacy endpoints as well as
safety, immunogenicity and pharmacokinetic parameters
were also measured.
Results 596 patients were randomised to either SB4
(N=299) or ETN (N=297). The ACR20 response rate at
week 24 in the per-protocol set was 78.1% for SB4 and
80.3% for ETN. The 95% CI of the adjusted treatment
difference was −9.41% to 4.98%, which is completely
contained within the predeﬁned equivalence margin of
−15% to 15%, indicating therapeutic equivalence
between SB4 and ETN. Other efﬁcacy endpoints and
pharmacokinetic endpoints were comparable. The incidence
of treatment-emergent adverse events was comparable
(55.2% vs 58.2%), and the incidence of antidrug antibody
development up to week 24 was lower in SB4 compared
with ETN (0.7% vs 13.1%).
Conclusions SB4 was shown to be equivalent with ETN
in terms of efﬁcacy at week 24. SB4 was well tolerated
with a lower immunogenicity proﬁle. The safety proﬁle of
SB4 was comparable with that of ETN.
Trial registration numbers NCT01895309, EudraCT
2012-005026-30.
INTRODUCTION
Etanercept is a recombinant human tumour necrosis
factor (TNF) receptor p75Fc fusion protein.
Etanercept is well established and has been widely
used in clinical practice for about 15 years, with a
well-characterised pharmacological, efﬁcacy and
safety proﬁle.1–5 Originally licensed for use in
moderate to severe rheumatoid arthritis (RA), the
therapeutic indications have been stepwise extended
and comprise treatment of patients with polyarticular
juvenile idiopathic arthritis, psoriatic arthritis,
ankylosing spondylitis, psoriasis and also paediatric
psoriasis. Recently, etanercept has been also approved
for use in non-radiographic axial spondyloarthritis
by the European Medicines Agency (EMA).6
A biosimilar is a biological medicinal product
that contains a version of the active substance of an
already authorised original biological medicinal
product (reference medicinal product). A biosimilar
demonstrates similarity to the reference medicinal
product in terms of quality characteristics, bio-
logical activity, safety and efﬁcacy based on a com-
prehensive comparability exercise.7–9
SB4 has been developed as a biosimilar to the
reference product etanercept (ETN). SB4 is pro-
duced by recombinant DNA technology in Chinese
hamster ovary mammalian cell expression system.
Similar structural, physicochemical and biological
activities of SB4 and ETN have been shown using
state-of-the-art analytical methods including peptide
mapping, TNF-α binding assay and TNF-α neutral-
isation cell-based assay. Equivalence in the pharma-
cokinetics (PK) between SB4 and ETN was
demonstrated in a phase I study conducted in
healthy male subjects.10 The objective of this study
was to compare the efﬁcacy, safety, PK and immuno-
genicity of SB4 and ETN in patients with RA.
METHODS
Patients
Patients aged 18–75 years who have been diagnosed
with RA according to the revised 1987 American
College of Rheumatology (ACR) criteria for
≥6 months and ≤15 years prior to screening were
eligible for the study. Patients had to have active
disease deﬁned as ≥6 swollen and ≥6 tender joints
and either erythrocyte sedimentation rate (ESR)
≥28 mm/h or serum C reactive protein (CRP)
≥1.0 mg/dL despite methotrexate (MTX) treatment
for ≥6 months (stable dose of 10–25 mg/week for
≥4 weeks prior to screening). Non-steroidal anti-
inﬂammatory drugs and oral glucocorticoids
(equivalent to ≤10 mg prednisolone) were permit-
ted if received at a stable dose for ≥4 weeks prior to
randomisation.
Major exclusion criteria consisted of previous
treatment with any biological agents, history of
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lymphoproliferative disease, congestive heart failure (New York
Heart Association Class III/IV) or demyelinating disorders, diag-
nosis of active tuberculosis (TB) and pregnancy or breast
feeding at screening.
Additional eligibility criteria are listed in online
supplementary appendix 1.
Study design
This phase III, randomised, double-blind, parallel-group study
was conducted at 73 centres across 10 countries in Europe,
Latin America and Asia. Patients were randomised in a 1:1 ratio
to receive 50 mg of either SB4 or ETN (see online
supplementary appendix 2). Patients self-administered SB4 or
ETN once weekly for up to 52 weeks via subcutaneous injec-
tion. All patients had to take MTX (10–25 mg/week) and folic
acid (5–10 mg/week) during the study. This study is currently
ongoing, and this report represents efﬁcacy data up to 24 weeks
of treatment and safety data up to the 24-week interim report
data cut-off point (21 July 2014).
Study endpoints
The primary endpoint was the ACR20 response rate at week 24.
Other efﬁcacy endpoints were the ACR50 and ACR70
responses, the numeric index of the ACR response (ACR-N),
change in the disease activity score in 28 joints (DAS28) based
on ESR, the area under the curve (AUC) of the ACR-N, AUC of
the change in DAS28 and the European League Against
Rheumatism (EULAR) response. Safety endpoints included inci-
dence of adverse events (AEs) and serious adverse events (SAEs).
PK analyses were performed in the PK population, which
included a subset of patients from pre-designated study sites.
Key PK endpoints included serum trough concentration
(Ctrough) and area under the concentration–time curve during
the dosing interval (AUCτ) at steady state. Serum concentrations
were determined using a validated ELISA, and PK parameters
were calculated by non-compartmental analyses (WinNonlin
V.5.2 or higher, Pharsight, Mountain View, California, USA).
Immunogenicity was measured in all patients. The immuno-
genicity endpoints were incidence of antidrug antibodies (ADAs)
and neutralising antibodies (NAbs). A single-assay approach
with SB4 tag was used to assess immunogenicity. ADAs were
measured using validated electrochemiluminescence immunoas-
says, and NAbs were measured using a competitive ligand-
binding assay.
Details on the serum measurement and ADA detection assay
can be found in online supplementary appendix 3.
Statistical analyses
Sample size was determined using the historical data for the
equivalence test. The expected ACR20 response rate at week 24
for both SB4 and ETN was expected to be 60% from the previ-
ous ETN pivotal studies.11–13 Based on the expected response
rate, the equivalence margin of −15% to 15% at week 24 for
ACR20 response rate was calculated in line with the US Food
and Drug Administration Guidance for Industry Non-Inferiority
Clinical Trials and the Committee for Medicinal Products for
Human Use Guideline on the Choice of the Non-inferiority
Margin and was also agreed with the regulatory agencies.14 15
Given a two-sided α level of 0.05 and 80% power, the two-
sided 15% equivalence margin required 438 patients for the
per-protocol set (PPS). Assuming 20% loss of patients from the
PPS, the study required a minimum of 548 randomised patients.
The primary efﬁcacy analysis for ACR20 response at week 24
was performed on the PPS in which patients completed week
24 visit, received 80–120% of both the expected number of
study drug administrations and the expected sum of MTX
doses, and did not have any major protocol deviations affecting
the efﬁcacy assessment. To declare the equivalence between the
two treatment groups, the 95% CI of the adjusted treatment dif-
ference had to be entirely contained within the equivalence
margin of −15% to 15%. The 95% CI of the difference of
ACR20 response rates was estimated non-parametrically using
the Mantel–Haenszel weights for region while adjusting for the
baseline CRP. As a sensitivity analysis, the same analysis was
repeated for the full analysis set (FAS) with missing data at
week 24 considered as non-responses to explore the robustness
of the results. Similar analyses were performed for ACR50 and
ACR70 responses at week 24. Other secondary endpoints are
summarised descriptively.
In addition, the exponential time–response model for ACR20
response rate was used to investigate the treatment difference
during the time course of the study up to week 24.16 Details on
the time–response model are provided in online supplementary
appendix 4.
Safety and immunogenicity endpoints were analysed descrip-
tively on the safety set that included all patients who received at
least one dose of study drug. PK endpoints were summarised
descriptively on the PK population who had at least one PK
sample collected.
The analyses were performed using SAS V.9.2 software (SAS
Institute, Cary, North Carolina, USA).
RESULTS
Patient disposition and baseline characteristics
Patient screening began in June 2013, and the 24-week evalu-
ation of the last patient occurred in April 2014. Overall, 777
patients were screened, of whom 596 patients were randomised.
A total of 551 patients completed 24 weeks of treatment and
481 (80.7%) patients were included in the PPS (75 patients
were excluded from the PPS due to protocol deviations, see
online supplementary table S1). Patients withdrew before week
24 mainly due to AEs (3.7%) and withdrawal of consent (2.7%)
(ﬁgure 1). The demographic and baseline disease characteristics
were comparable between treatment groups (table 1).
Efﬁcacy
The ACR20 response rate at week 24 in the PPS was 78.1% for
SB4 and 80.3% for ETN. The 95% CI of the adjusted difference
(SB4—ETN) in ACR20 response rate was within the predeﬁned
equivalence margin of −15% to 15% in both the PPS (95% CI
−9.41% to 4.98%) and FAS (95% CI −5.24% to 9.07%), indi-
cating therapeutic equivalence between SB4 and ETN (ﬁgure 2).
The time–response models of SB4 and ETN up to week 24 in the
PPS were estimated to be equivalent since the treatment differ-
ence in terms of the two-norm difference was 12.7 and the 95%
CI was −4.6 to 30.0, where the upper limit 30.0 was less than
the pre-speciﬁed equivalence margin of 83.28 (ﬁgure 3).
The ACR50 and ACR70 response rates at week 24 in the PPS
and FAS were equivalent between SB4 and ETN. The ACR50
response rate was 46.6% vs 42.3%, and the ACR70 response
rate was 25.5% vs 22.6% in the PPS for SB4 and ETN, respect-
ively, as shown in ﬁgure 2.
Subgroup analyses on the ACR response rates in PPS showed
comparable results regardless of ADA status. The proportion of
patients who achieved ACR20 response rate among patients
who tested negative for antibodies against ETN was 78.0% in
SB4 and 81.5% in ETN (95% CI −11.12% to 3.99%) (see
online supplementary table S2).
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Figure 1 Summary of patient disposition. A total of 777 patients were screened and 181 patients were excluded mainly due to not meeting the
exclusion criteria. Multiple screening failure reasons were possible. All patients randomised were included in the full analysis set and the safety set.
Of the 551 patients who completed 24 weeks of treatment, 481 patients were included in the per-protocol set. ETN, etanercept.
Table 1 Baseline demographics and disease characteristics
SB4 50 mg ETN 50 mg Total
N=299 N=297 N=596
Age (years), mean (SD) 52.1 (11.72) 51.6 (11.63) 51.8 (11.67)
Age group, n (%)
<65 years 253 (84.6) 262 (88.2) 515 (86.4)
≥65 years 46 (15.4) 35 (11.8) 81 (13.6)
Gender n (%)
Male 50 (16.7) 44 (14.8) 94 (15.8)
Female 249 (83.3) 253 (85.2) 502 (84.2)
Race, n (%)
White 279 (93.3) 273 (91.9) 552 (92.6)
American Indian or Alaskan Native 5 (1.7) 7 (2.4) 12 (2.0)
Asian 11 (3.7) 13 (4.4) 24 (4.0)
Other 4 (1.3) 4 (1.3) 8 (1.3)
Weight (kg), mean (SD) 72.5 (15.93) 71.0 (14.63) 71.8 (15.30)
Height (cm), mean (SD) 164.4 (8.78) 164.4 (8.55) 164.4 (8.66)
BMI (kg/m2), mean (SD) 26.8 (5.51) 26.3 (5.30) 26.6 (5.41)
Disease duration (years), mean (SD) 6.0 (4.20) 6.2 (4.41) 6.1 (4.30)
Duration of MTX use (months), mean (SD) 48.2 (39.87) 47.1 (40.77) 47.7 (40.29)
MTX dose (mg/week), mean (SD) 15.6 (4.52) 15.5 (4.60) 15.5 (4.56)
Swollen joint count (0–66), mean (SD) 15.4 (7.48) 15.0 (7.30) 15.2 (7.39)
Tender joint count (0–68), mean (SD) 23.5 (11.90) 23.6 (12.64) 23.5 (12.26)
HAQ-DI (0–3), mean (SD) 1.49 (0.553) 1.50 (0.560) 1.50 (0.556)
Physician global assessment VAS (0–100), mean (SD) 62.2 (15.09) 63.2 (14.76) 62.7 (14.92)
Subject global assessment VAS (0–100), mean (SD) 61.7 (18.97) 63.0 (17.70) 62.4 (18.35)
Subject pain assessment VAS (0–100), mean (SD) 61.8 (20.22) 62.3 (19.22) 62.1 (19.71)
DAS28 (ESR), mean (SD) 6.5 (0.91) 6.5 (0.88) 6.5 (0.89)
C reactive protein (mg/dL), mean (SD) 1.5 (2.00) 1.3 (1.60) 1.4 (1.81)
Erythrocyte sedimentation rate (mm/h), mean (SD) 46.5 (22.10) 46.4 (22.62) 46.5 (22.34)
Rheumatoid factor positive, n (%) 237 (79.3) 231 (77.8) 468 (78.5)
BMI, body mass index; DAS28, disease activity score in 28 joints; ETN, reference product etanercept; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment
Questionnaire-Disability Index; MTX, methotrexate; VAS, visual analogue scale.
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The mean improvement in DAS28 from baseline was 2.6 and
2.5 at week 24 in SB4 and ETN, respectively (95% CI −0.14 to
0.28) (ﬁgure 4A). The proportion of patients achieving good or
moderate EULAR response (ﬁgure 4B), low-disease activity
score or remission (ﬁgure 4C) at week 24 according to DAS28
were similar between SB4 and ETN. The ACR-N at week 24
was 45.0% in SB4 and 43.7% in ETN. The AUC of ACR-N up
to week 24 (5822.2 vs 5525.0) and the AUC of change in
DAS28 from baseline up to week 24 (358.3 vs 343.5) were
comparable between SB4 and ETN.
Safety
Overall, 165 (55.2%) patients in SB4 and 173 (58.2%) patients
in ETN reported at least one treatment-emergent adverse event
(TEAE). Frequently occurring TEAEs by preferred term are
shown in table 2, and the most frequently reported TEAE were
upper respiratory tract infection (7.0%) and alanine aminotrans-
ferase increased (5.0%) in the SB4 and injection site erythema
(11.1%), upper respiratory tract infection (5.1%) and nasophar-
yngitis (5.1%) in ETN. Most of the TEAEs were mild to moder-
ate in severity, and TEAEs considered related to the study drug
were reported in 83 (27.8%) and 106 (35.7%) patients for SB4
and ETN, respectively. Serious TEAEs were reported in 13
patients each in SB4 and ETN and 34 patients discontinued
treatment due to TEAE (15 (5.0%) patients vs 19 (6.4%)
patients).
A total of 25 patients (13 patients for SB4 and 12 patients for
ETN) were diagnosed at screening with latent TB but entered
the study after completing at least 30 days of treatment for
latent TB and while receiving treatment. None of these patients
or any other patients developed active TB during the study.
Other serious infections were reported in one (0.3%) patient in
SB4 and four (1.3%) patients in ETN. Malignancies were
reported in three (1.0%) patients in SB4 (basal cell carcinoma,
breast cancer and lung cancer metastatic) and in one (0.3%)
patient in ETN (invasive ductal breast carcinoma).
Injection site reactions (ISRs), counted by the high-level
group term of administration site reactions, occurred in fewer
patients in SB4 compared with ETN. There were 22 ISRs
reported in 11 (3.7%) patients vs 156 ISRs reported in 51
(17.2%) patients in SB4 and ETN, respectively (p<0.001).
Most of the ISRs occurred early (between weeks 2 and 8) and
were mild in severity. The incidence of ISR for SB4 and ETN
were 3.7% vs 17.1% in ADA-positive patients and 0.0% vs
17.9% in ADA-negative patients, respectively (see online supple-
mentary table S3).
One death was reported in the SB4 treatment group due to
cardiorespiratory failure, which was not considered related to
the study drug.
Pharmacokinetics
PK analyses were performed on 79 patients (41 patients in SB4
and 38 patients in ETN).
Ctrough were comparable at each time point between SB4
(ranging from 2.419 to 2.886 μg/mL in weeks 2–24) and ETN
(ranging from 2.066 to 2.635 μg/mL in weeks 2–24) (see online
supplementary ﬁgure S2). The AUCτ at week 8 was 676.4 vs
520.9 μg h/mL and the inter-subject variability (CV%) was
37.7% vs 50.1% in SB4 and ETN, respectively (see online sup-
plementary ﬁgure S3).
Immunogenicity
The incidence of ADA was signiﬁcantly lower in SB4 compared
with ETN. Two (0.7%) patients in SB4 and 39 (13.1%) patients
in ETN tested positive at least once up to week 24 (p<0.001),
and only one sample from the ETN group had neutralising cap-
acity. The ADAs appeared early (between weeks 2 and 8), and
most of the ADAs disappeared after week 12 (see online
supplementary appendix 9).
DISCUSSION
In this randomised, double-blind, parallel-group, multicentre
study, the efﬁcacy, safety and immunogenicity of SB4 were com-
pared with those of ETN in patients with moderate to severe
Figure 2 American College of Rheumatology (ACR) response rates at
week 24. The adjusted treatment difference and its 95% CI were analysed
with baseline C reactive protein as a covariate and stratiﬁed by region.
(A) ACR 20% (ACR20) response rates of SB4 and etanercept (ETN) in the
per-protocol set and full analysis set. (B) ACR50 response rates of SB4 and
ETN in the per-protocol set and full analysis set. (C) ACR70 response rates
of SB4 and ETN in the per-protocol set and full analysis set. *One patient
from the SB4 group was excluded from the FAS due to missing efﬁcacy
data at baseline.
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RA despite MTX treatment. Equivalence of efﬁcacy between
SB4 and ETN was demonstrated and the safety of SB4 was gen-
erally comparable to ETN.
The primary endpoint at week 24 was met: the 95% CI of
the adjusted treatment difference between SB4 and ETN in
ACR20 response rate was within the predeﬁned equivalence
margin of −15% to 15%. The ACR20 responses observed in
this study (73.8% for SB4 and 71.7% for ETN in FAS) were
within the range of ACR20 response rates reported in pivotal
studies with ETN (49–86%)4 11–13 17–19 but slightly higher than
what was assumed (60%). Since active treatment is used in both
groups, biosimilar studies tend to show higher ACR20 response
rates20–22 compared with pivotal controlled studies.
As the primary efﬁcacy assessment (ACR20 response at week 24)
was evaluated at a time point in the therapeutic plateau, various
efﬁcacy endpoints and statistical methods were applied to detect
any non-equivalence in efﬁcacy and to support the robustness of
the primary efﬁcacy analysis. The ACR20 response rate, ACR-N
and DAS28 were measured at several different time points early in
the treatment period. The time–response curves of SB4 and ETN
Figure 3 Estimated time–response curves of American College of
Rheumatology 20% (ACR20) response rate up to week 24 in the
per-protocol set. For details of the estimation process, please refer to
the main text. ETN, etanercept.
Figure 4 Changes over time in the
disease activity score in 28 joints
(DAS28) and European League Against
Rheumatism (EULAR) responses at
week 24 in the full analysis set. (A)
Change in DAS28 up to week 24. (B)
EULAR response based on DAS28. (C)
Proportion of patients achieving
low-disease activity score (LDAS)
deﬁned as DAS28 ≤3.2 and remission
deﬁned as DAS28 ≤2.6. ETN,
etanercept.
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up to week 24 showing the ACR20 response over time were esti-
mated to be equivalent, and the AUC of ACR-N up to week 24 and
AUC of the change in DAS28 (ESR) from baseline up to week 24
were comparable between SB4 and ETN, indicating that the efﬁ-
cacy of SB4 over time was similar to ETN.
Overall, the safety proﬁle of SB4 was comparable with that of
ETN and was similar to those observed in the pivotal trials with
ETN. There were no cases of active TB and only one patient in
SB4 and four patients in ETN reported serious infection, which
is lower than 6.3% shown in ETN product information.6
Malignancies were reported in three (1.0%) patients in SB4 and
one (0.3%) patient in ETN. The incidence of malignancy
observed in this study is similar to the previously conducted
studies.11 23 24 Interestingly, ISRs were reported in fewer
patients from SB4 compared with ETN (3.7% vs 17.2%). The
proportion of patients who experienced at least one ISR from
ETN group in this study (17.2%) is in line with recently con-
ducted studies with 50 mg once weekly ETN,13 and most ISRs
occurred in the ﬁrst month, which is in accordance with the ref-
erence product label.6 26 Although it is unclear why the inci-
dence of ISR was lower in SB4 compared with ETN, the
difference in drug product formulation and container closure
system may have contributed to the lower ISR. The only differ-
ence in drug composition between SB4 and ETN is the absence
of L-arginine in SB4. It has not been shown that L-arginine is
associated with increased risk of ISR; however, we cannot pre-
clude the sole difference in formulation (absence of L-arginine)
as the cause of ISR. In addition, natural rubber latex known to
cause hypersensitivity reactions has not been used in the needle
shield of SB4. There appears to be no correlation between ISR
and ADA development, which is consistent with previously con-
ducted studies.25
In this study, Ctrough and steady state PK was investigated in a
subset of population to provide supporting evidence to the
phase I comparative PK study in healthy subjects, which demon-
strated similar PK behaviour. In the phase III study, the Ctrough
values were comparable between SB4 and ETN at each time
point and AUCτ at steady state was relatively higher in SB4 com-
pared with ETN; however, the numerical difference is likely due
to an inherent high inter-subject variability (37.7% vs 50.1%).
The incidence of ADA shown in the ETN group of this study
(13.1%) is seemingly higher compared with what has been
reported in the previous studies.6 In this study, the assay used to
detect immunogenicity was more sensitive and immunogenicity
was measured more frequently; most of the ADAs were detected
at week 4 in this study while immunogenicity was not measured
at these time points in the previous studies and could have
resulted in higher overall incidence of ADA in this study.13 25 27
The characteristics of antibodies detected in this study were gen-
erally transient and non-neutralising, which is in accordance
with those established with ETN in previous studies.6 25 Since
SB4 tagged single-assay approach was used to detect immuno-
genicity, the assay method does not seem to have caused the
lower incidence of ADA observed in SB4 compared with ETN
(0.7% vs 13.1%). There are product-speciﬁc factors known to
affect immunogenicity, such as product origin (foreign or
human), product aggregates, impurities, container closure
system;28–31 however, factors contributing to lower immunogen-
icity of SB4 are to be further investigated. Yet, according to the
EMA guideline on biosimilars7 the lower immunogenicity of
SB4 does not preclude classiﬁcation as biosimilar since clinical
efﬁcacy of SB4 and ETN were equivalent in patients with
ADA-negative results and no apparent correlation between ADA
and clinical response or safety was observed.7 25 32 33
To date, this is the ﬁrst global, multicentre study comparing
an ETN biosimilar to reference product ETN. Conﬁrmed
equivalence of SB4 and ETN in this study may provide an alter-
native treatment option for RA and allow better access to biolo-
gics for patients.
CONCLUSIONS
SB4 was shown to be equivalent in terms of clinical efﬁcacy
when compared with ETN. SB4 was well tolerated with a com-
parable safety proﬁle to ETN.
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Table 2 Treatment-emergent adverse events reported in ≥2%
patients by preferred term, n (%)
Preferred term
SB4 50 mg ETN 50 mg
N=299 N=297
Upper respiratory tract infection 21 (7.0) 15 (5.1)
Alanine aminotransferase increased 15 (5.0) 14 (4.7)
Nasopharyngitis 14 (4.7) 15 (5.1)
Headache 13 (4.3) 8 (2.7)
Hypertension 10 (3.3) 10 (3.4)
Aspartate aminotransferase increased 7 (2.3) 8 (2.7)
Viral infection 7 (2.3) 5 (1.7)
Injection site erythema 6 (2.0) 33 (11.1)
Rheumatoid arthritis 6 (2.0) 9 (3.0)
Bronchitis 6 (2.0) 6 (2.0)
Diarrhoea 5 (1.7) 7 (2.4)
Pharyngitis 4 (1.3) 8 (2.7)
Urinary tract infection 4 (1.3) 7 (2.4)
Lymphocyte count decreased 4 (1.3) 6 (2.0)
Cough 3 (1.0) 10 (3.4)
Erythema 2 (0.7) 10 (3.4)
Dizziness 2 (0.7) 7 (2.4)
Injection site rash 2 (0.7) 6 (2.0)
Injection site reaction 1 (0.3) 7 (2.4)
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